Congratulations!

[Valid RSS] This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

Source: http://investor.arbutusbio.com/rss/news-releases.xml

  1. <?xml version="1.0" encoding="utf-8"?>
  2. <rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0" xml:base="https://investor.arbutusbio.com/">
  3.  <channel>
  4.    <title>Arbutus Biopharma Corporation News Releases</title>
  5.    <link>https://investor.arbutusbio.com/</link>
  6.    <description>Arbutus Biopharma Corporation News Releases</description>
  7.    <language>en</language>
  8.    
  9.    <item>
  10.  <title>Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update</title>
  11.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-first-quarter-2024-financial-results-and</link>
  12.  <description>End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in</description>
  13.  <pubDate>Thu, 02 May 2024 07:30:18 -0400</pubDate>
  14.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  15.    <guid isPermaLink="false">18531</guid>
  16.    </item>
  17. <item>
  18.  <title>Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024</title>
  19.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-retirement-chief-scientific-officer-michael-j</link>
  20.  <description>WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV)</description>
  21.  <pubDate>Thu, 02 May 2024 07:25:10 -0400</pubDate>
  22.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  23.    <guid isPermaLink="false">18516</guid>
  24.    </item>
  25. <item>
  26.  <title>Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update</title>
  27.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-report-first-quarter-2024-financial-results-and-provide</link>
  28.  <description>WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it</description>
  29.  <pubDate>Thu, 18 Apr 2024 07:30:28 -0400</pubDate>
  30.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  31.    <guid isPermaLink="false">18501</guid>
  32.    </item>
  33. <item>
  34.  <title>Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna</title>
  35.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its</link>
  36.  <description>WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the</description>
  37.  <pubDate>Thu, 04 Apr 2024 08:31:17 -0400</pubDate>
  38.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  39.    <guid isPermaLink="false">18461</guid>
  40.    </item>
  41. <item>
  42.  <title>Arbutus to Participate in Two Upcoming Investor Conferences</title>
  43.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-participate-two-upcoming-investor-conferences-0</link>
  44.  <description>WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the</description>
  45.  <pubDate>Fri, 08 Mar 2024 07:30:28 -0500</pubDate>
  46.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  47.    <guid isPermaLink="false">18441</guid>
  48.    </item>
  49. <item>
  50.  <title>Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update</title>
  51.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-fourth-quarter-and-year-end-2023-financial</link>
  52.  <description>On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial with imdusiran in first half of 2024 Claim Construction for Moderna LNP litigation occurred on</description>
  53.  <pubDate>Thu, 29 Feb 2024 07:30:20 -0500</pubDate>
  54.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  55.    <guid isPermaLink="false">18406</guid>
  56.    </item>
  57. <item>
  58.  <title>Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update</title>
  59.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-report-fourth-quarter-and-year-end-2023-financial</link>
  60.  <description>WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it</description>
  61.  <pubDate>Thu, 15 Feb 2024 07:30:08 -0500</pubDate>
  62.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  63.    <guid isPermaLink="false">18391</guid>
  64.    </item>
  65. <item>
  66.  <title>Arbutus Announces 2024 Corporate Objectives and Provides Financial Update</title>
  67.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides</link>
  68.  <description>Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a third Phase 2a clinical trial evaluating imdusiran and an approved PD-L1 monoclonal antibody expected</description>
  69.  <pubDate>Mon, 08 Jan 2024 07:30:33 -0500</pubDate>
  70.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  71.    <guid isPermaLink="false">18336</guid>
  72.    </item>
  73. <item>
  74.  <title>Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®</title>
  75.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-and-barinthus-bio-present-preliminary-data</link>
  76.  <description>The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation WARMINSTER, Pa. and OXFORD, United Kingdom, Nov.</description>
  77.  <pubDate>Thu, 09 Nov 2023 16:01:41 -0500</pubDate>
  78.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  79.    <guid isPermaLink="false">18306</guid>
  80.    </item>
  81. <item>
  82.  <title>Arbutus to Present at Jefferies London Healthcare Conference</title>
  83.  <link>https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-jefferies-london-healthcare-conference-0</link>
  84.  <description>WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today</description>
  85.  <pubDate>Wed, 08 Nov 2023 07:30:53 -0500</pubDate>
  86.    <dc:creator>Arbutus Biopharma Corporation News Releases</dc:creator>
  87.    <guid isPermaLink="false">18296</guid>
  88.    </item>
  89.  
  90.  </channel>
  91. </rss>
  92.  

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

  1. Download the "valid RSS" banner.

  2. Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)

  3. Add this HTML to your page (change the image src attribute if necessary):

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=http%3A//investor.arbutusbio.com/rss/news-releases.xml

Home · About · News · Docs · Terms

 
Copyright © 2002-9 Sam Ruby, Mark Pilgrim, Joseph Walton, and Phil Ringnalda